SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

CIPLA

BSE: 500087 18 Aug 2025
Healthcare
₹ 1563
Cipla Ltd., specializes in Pharmaceuticals within the Healthcare sector.

CIPLA - Share Price & Details

Market Cap
₹1,26,010
High /Low
1,702 / 1,310
Stock P/E
23.4
Book Value
₹386.0
Dividend Yield
0.83
ROCE
22.7
ROE
₹17.8
Face Value
2.0
PEG Ratio
0.91
EVEBITDA
₹15.4
Debt
438
CMP / FCF
45.0
Debt to equity
₹0.01
NP Ann
5,269
High price all time
1,702
Piotroski score
₹7.0
Graham Number
762.0
No. Eq. Shares
80.8
Net CF
₹30.3
Net profit
5,385
Price to book value
4.03
Interest Coverage
₹121.0
Low price all time
84.7
Industry PE
33.1
Reserves
₹31,032
Free Cash Flow
₹3,490

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
CIPLA LTD.53172.413031.350461.716.121,26,01023.4
TORRENT PHARMACEUTICALS LTD.26110.05510.026160.016.2812234360.6
Max Healthcare Institute Limit7738.71660.36940.21.711867098.9

Peer Comparison Chart


About CIPLA

Cipla Ltd.,, with Security Code 500087, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Cipla Limited's (NSE:CIPLA) one-year returns climbed after last week's 5.3% gain, institutional investors must be happy

(17 Aug 2025)
Key Insights Given the large stake in the stock by institutions, Cipla's stock price might be vulnerable to their...
Read more →

Cipla shares jump 2.6% on Wednesday, among top gainers on Nifty 50

(14 Aug 2025)
Cipla's stock was among the top gainers on Nifty 50 in Wednesday's session. As of yesterday's close, Cipla was at Rs 1,561.00,...
Read more →

Cipla Ltd spurts 2.93%, gains for third straight session

(13 Aug 2025)
Cipla Ltd is quoting at Rs 1566.2, up 2.93% on the day as on 12:49 IST on the NSE. The stock is up 0.15% in last one year as compared to a...
Read more →

SES ESG Research Pvt Ltd assigns ESG rating of 69.3 to Cipla Ltd

(12 Aug 2025)
SES ESG Research Private Limited, a SEBI registered ESG Rating Provider ("SES"), has independently assigned the Environmental, Social,...
Read more →

Growth prescription: The future is specialty; Sun Pharma, Dr Reddy’s, Cipla lead, says Nomura

(12 Aug 2025)
Nomura's June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Zydus posting strong specialty drug...
Read more →

Cipla: India business reset and emerging market challenges crimp earnings expectations

(07 Aug 2025)
Shares of pharmaceutical major Cipla Ltd lost about 3% leading the losses in the NSE Nifty stocks at Wednesday noon trade.
Read more →

Company Updates